Human milk oligosaccharides (HMOs) are a diverse group of complex carbohydrates that are the third most abundant solid component of human breast milk, after lactose and lipids. They are indigestible by the infant but serve multiple biological functions, particularly in shaping the infant gut microbiome and supporting immune development.
Composition and Structure
- HMOs consist of five monosaccharide building blocks: glucose, galactose, N‑acetylglucosamine, fucose, and sialic acid (N‑acetylneuraminic acid).
- Over 200 distinct HMO structures have been identified, ranging from simple linear trisaccharides to highly branched decasaccharides.
- The core lactose unit (galactose‑β‑1,4‑glucose) serves as the scaffold to which additional monosaccharides are added through specific glycosidic linkages.
Major Categories
- Neutral non‑fucosylated HMOs (e.g., lacto‑N‑tetrose).
- Neutral fucosylated HMOs (e.g., 2′‑fucosyllactose, 3‑fucosyllactose).
- Acidic (sialylated) HMOs (e.g., 3′‑sialyllactose, 6′‑sialyllactose).
The relative abundance of each category varies among mothers, largely due to genetic polymorphisms in the secretor (FUT2) and Lewis (FUT3) genes that influence fucosyltransferase activity.
Physiological Functions
| Function | Evidence/Mechanism |
|---|---|
| Prebiotic effect | HMOs selectively stimulate the growth of beneficial gut bacteria, especially Bifidobacterium species such as B. longum subsp. infantis, which possess specific HMO‑utilizing genes. |
| Pathogen decoy | Structural similarity to host cell surface glycans allows HMOs to bind bacterial and viral adhesins, preventing attachment to the intestinal epithelium (e.g., inhibition of Campylobacter jejuni, norovirus, and certain strains of Escherichia coli). |
| Modulation of immune responses | HMOs influence epithelial cell signaling, dendritic cell maturation, and cytokine production, contributing to reduced inflammation and improved barrier function. |
| Neurological development | Some HMOs cross the intestinal barrier and have been detected in systemic circulation; animal studies suggest roles in brain development and cognition, though definitive human data are limited. |
| Metabolic programming | Early exposure to HMOs is associated with lower risk of obesity and diabetes later in life, potentially mediated by microbiota‑driven metabolic pathways. |
Clinical and Nutritional Relevance
- Infant formula supplementation: Synthetic or bovine‑derived analogs of the most abundant HMOs, such as 2′‑fucosyllactose (2′‑FL) and lacto‑N‑neotetraose (LNnT), have been added to commercial formulas. Clinical trials indicate benefits comparable to breast milk in terms of stool consistency, infection rates, and microbiota composition.
- Therapeutic potential: Research is ongoing into HMO‑based interventions for conditions such as necrotizing enterocolitis, allergic diseases, and adult gut dysbiosis.
- Individual variability: Maternal secretor status leads to considerable differences in HMO profiles; infants of non‑secretor mothers receive lower levels of fucosylated HMOs, which may influence their early microbial colonization patterns.
Regulation and Safety
HMOs are Generally Recognized As Safe (GRAS) by the U.S. Food and Drug Administration when used in infant formula at concentrations replicating those found in human milk (approximately 5–15 g/L). Production of HMOs for commercial use employs microbial fermentation (e.g., engineered Escherichia coli or yeast) or enzymatic synthesis to achieve high purity.
Research Gaps
- Long‑term health outcomes associated with specific HMO exposure remain to be fully clarified.
- The mechanisms by which HMOs influence systemic immunity and neurodevelopment require further elucidation.
References
(Selected peer‑reviewed sources)
- Bode, L. (2012). Human milk oligosaccharides: Every baby needs a sugar mama. Glycobiology, 22(9), 1147‑1162.
- Newburg, D. S., & Walker, W. A. (2007). Protection of the neonate by the innate immune system of developing gut and microbiota. J. Pediatr., 150(1), S13‑S21.
- Zivkovic, A. M., & Barile, D. (2020). Human milk oligosaccharides: The next frontier in infant nutrition. Nutrients, 12(7), 2045.
This entry reflects the current scientific consensus as of 2026.
